A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18

Expert Review of Vaccines

Volumn 11, Issue 4, 2012, Pages 395-406

  Goldstone, Stephen E ^a   Vuocolo, Scott ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

cervical cancer; HPV; papillomavirus; vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; MENINGOCOCCUS VACCINE; PLACEBO; RECOMBINANT HEPATITIS B VACCINE; WART VIRUS VACCINE;

ADENOCARCINOMA IN SITU; ANUS CARCINOMA; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DRUG SAFETY; GROUPS BY AGE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; INFECTION PREVENTION; INJECTION SITE REACTION; MALE HOMOSEXUAL; NONHUMAN; OROPHARYNX CANCER; PAPILLOMAVIRUS INFECTION; PENILE INTRAEPITHELIAL NEOPLASIA; PENIS CANCER; PRECANCER; PREVALENCE; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION REACTION; VAGINA CANCER; VAGINAL INTRAEPITHELIAL NEOPLASIA; VIRUS CARCINOGENESIS; VULVA CANCER; VULVAR INTRAEPITHELIAL NEOPLASIA;

CONDYLOMATA ACUMINATA; DRUG APPROVAL; EUROPEAN UNION; FEMALE; HUMANS; MALE; OROPHARYNGEAL NEOPLASMS; PAPILLOMA; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84860589618     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.20     Document Type: Review

References (105)

1. Bonnez W. Papillomavirus. In: Clinical Virology (2nd Edition). Richman DD, Whitley RJ, Hayden FG (Eds). ASM Press, Washington, DC, USA, 557-596 (2002).
2. Stanley M. Pathology and epidemiology of HPV infection in females. Gynecol. Oncol. 117(2 Suppl. 1), S5-S10 (2010).
3. Muñoz N, Bosch FX, de Sanjosé S et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348(6), 518-527 (2003). (Pubitemid 36159887)
4. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int. J. Cancer 128(4), 927-935 (2011).
5. Muñoz N, Castellsague X, de Gonzalez AB, Gissmann L. HPV in the etiology of human cancer. Vaccine 24(Suppl. 3), S1-S10 (2006).
6. Burchell AN, Winer RL, de Sanjose S, Franco EL. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine 24(Suppl. 3), S52-S61 (2006). (Pubitemid 44293018)
7. Collins S, Mazloomzadeh S, Winter H et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG 109, 96-98 (2002).
8. de Sanjose S, Diaz M, Castellsague X et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect. Dis. 7(7), 453-459 (2007). (Pubitemid 46962343)
9. Franceschi S, Herrero R, Clifford GM et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int. J. Cancer 119(11), 2677-2684 (2006). (Pubitemid 44691325)
10. Partridge JM, Hughes JP, Feng Q et al. Genital human papillomavirus infection in men: incidence and risk factors in a cohort of University students. J. Infect. Dis. 196(8), 1128-1136 (2007). (Pubitemid 47580267)
11. Giuliano AR, Lu B, Nielson CM et al. Agespecific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. J. Infect. Dis. 198(6), 827-835 (2008).
12. Chin-Hong PV, Vittinghoff E, Cranston RD et al. Age-specific prevalence of anal human papillomavirus infection in HIVnegative sexually active men who have sex with men: the EXPLORE study. J. Infect. Dis. 190(12), 2070-2076 (2004). (Pubitemid 39636353)
13. Nyitray A, Nielson CM, Harris RB et al. Prevalence of and risk factors for anal human papillomavirus infection in heterosexual men. J. Infect. Dis. 197(12), 1676-1684 (2008). (Pubitemid 351919631)
14. Goodman MT, Shvetsov YB, McDuffie K et al. Acquisition of anal human papillomavirus (HPV) infection in women: the Hawaii HPV Cohort study. J. Infect. Dis. 197(7), 957-966 (2008). (Pubitemid 351590023)
15. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 24(Suppl. 3), S11-S25 (2006). (Pubitemid 44404053)
16. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br. J. Cancer 89(1), 101-105 (2003). (Pubitemid 36897943)
17. de Sanjose S, Quint WG, Alemany L et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 11(11), 1048-1056 (2010).
18. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J. Clin. 55(2), 74-108 (2005).
19. Kane MA, Sherris J, Coursaget P, Aguado T, Cutts F. Chapter 15: HPV vaccine use in the developing world. Vaccine 24(Suppl. 3), S3/132-S3/139 (2006).
20. Arbyn M, Raifu AO, Autier P, Ferlay J. Burden of cervical cancer in Europe: estimates for 2004. Ann. Oncol. 18(10), 1708-1715 (2007). (Pubitemid 47506260)
21. Castellsague X, Diaz M, de Sanjose S et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J. Natl. Cancer Inst. 98, 303-314 (2006).
22. Wang SS, Sherman ME, Hildesheim A, Lacey JV, Devesa S. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer 100(5), 1035-1044 (2004). (Pubitemid 38232621)
23. Sherman ME, Wang SS, Carreon J, Devesa SS. Mortality trends for cervical squamous and adenocarcinoma in the United States - relation to incidence and survival. Cancer 103(6), 1258-1264 (2005). (Pubitemid 40328098)
24. Vizcaino AP, Moreno V, Bosch FX, Munoz N, Barros-Dios XM, Parkin DM. International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas. Int. J. Cancer 75(4), 536-545 (1998). (Pubitemid 28094098)
25. Bulk S, Visser O, Rozendaal L, Verheijen RHM, Meijer CJLM. Cervical cancer in the Netherlands 1989-1998: decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women. Int.J. Cancer 113(6), 1005-1009 (2005). (Pubitemid 40096882)
26. International Agency for Research on cancer. Handbooks of Cancer Prevention, Volume 9. Cervix Cancer Screening. IRAC Press, Lyon, France (2004).
27. Hopkins MP, Morley GW. A comparison of adenocarcinoma and squamous cell carcinoma of the cervix. Obstet. Gynecol. 77(6), 912-917 (1991).
28. Ferris DG, Cox JT, O'Connor DM, Wright VC, Foerster J. Modern Colposcopy, Textbook and Atlas (2nd Edition). Kendall/Hunt Publishing, Dubuque, IA, USA (2004).
29. Benedet JL, Bender H, Jones H, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int. J. Gynaecol. Obstet. 70(2), 209-262 (2000).
30. Peto J, Gilham C, Deacon J et al. Cervical HPV infectionand neoplasia in a large population-basedprospective study: the Manchester cohort. Br. J. Cancer 91, 942-953 (2004). (Pubitemid 39273789)
31. ASCUS-LSIL Triage Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am. J. Obstet. Gynecol. 188(6), 1393-1400 (2003).
32. ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am. J. Obstet. Gynecol. 188(6), 1383-1392 (2003).
33. Garland SM, Hernandez-Avila M, Wheeler CM et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 356(19), 1928-1943 (2007). (Pubitemid 46740303)
34. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356(19), 1915-1927 (2007).
35. de Villiers E-M, Fauquet C, Broker TR, Bernard H-U, zur Hausen H. Classification of papillomaviruses. Virology 324, 17-27 (2004). (Pubitemid 38737395)
36. Brown DR, Kjaer SK, Sigurdsson K et al. The impact of quadrivalent HPV (type 6/11/16/18) L1 VLP vaccine on infection and disease due to oncogenic non vaccine HPV types in generally HPV naive women aged 16-26. J. Infect. Dis. 199(7), 926-935 (2009).
37. Daling JR, Weiss NS, Klopfenstein LL, Cochran LE, Chow WH, Daifuku R. Correlates of homosexual behavior and the incidence of anal cancer. JAMA 247(14), 1988-1990 (1982). (Pubitemid 12133712)
38. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int. J. Cancer 124(7), 1626-1636 (2009).
39. Palefsky JM. Human papillomavirusrelated disease in men: not just a women's issue. J. Adolesc. Health 46(4 Suppl.), S12-S19 (2010).
40. Johnson LG, Madeleine MM, Newcomer LM, Schwartz SM, Daling JR. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer 101(2), 281-288 (2004). (Pubitemid 38890830)
41. Qualters JR, Lee NC, Smith RA, Aubert RE. Breast and cervical cancer surveillance, United States, 1973-1987. MMWR CDC Surveill. Summ. 41(2), 1-7 (1992).
42. Palefsky J M, Giuliano AR, Goldstone S et al. HPV vaccine against anal hpv infection and anal intraepithelial neoplasia. N. Engl. J. Med. 365, 1576-1585 (2011).
43. Vardas E, Giuliano A, Goldstone et al. External genital HPV prevalence and associated factors among heterosexual men on five continents. J. Infect. Dis. 203, 58-65 (2010).
44. Goldstone SE, Palefsky J, Giuliano A et al. Prevalence and risk factors for HPV infection in HIV serogenative men who have sex with men. J. Infect. Dis. 203, 66-74 (2010).
45. Goldstone SE. A case assignment methodology for determining quadrivalent HPV vaccine efficacy against AIN in men having sex with men. 26th Annual International Papillomavirus Conference and Clinical Workshop. QC, Canada, 3-8 July 2010.
46. Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract. Res. Clin. Obstet. Gynaecol. 20(2), 207-225 (2006). (Pubitemid 43380597)
47. Judson PL, Habermann EB, Baxter NN, Durham SB, Virnig BA. Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet. Gynecol. 107(5), 1018-1022 (2006).
48. Hampl M, Deckers-Figiel S, Hampl JA, Rein D, Bender HG. New aspects of vulvarcancer: changes in localization and age of onset. Gynecol. Oncol. 109(3), 340-345 (2008).
49. Joura EA. Epidemiology, diagnosis and treatment of vulvar intraepithelial neoplasia. Curr Opin Obstet Gynecol 14, 39-43 (2002). (Pubitemid 34177906)
50. Lenehan PM, Meffe F, Lickrish GM. Vaginal intraepithelial neoplasia - biologic aspects and management. Obstet. Gynecol. 68(3), 333-337 (1986). (Pubitemid 16046492)
51. Schneider A, Devilliers EM, Schneider V. Multifocal squamous neoplasia of the female genital-tract - significance of human papillomavirus infection of the vagina after hysterectomy. Obstet. Gynecol. 70(3), 294-298 (1987). (Pubitemid 17151643)
52. Aho M, Vesterinen E, Meyer B, Purola E, Paavonen J. Natural history of vaginal intraepithelial neoplasia. Cancer 68(1), 195-197 (1991).
53. Hampl M, Sarajuuri H, Wentzensen N, Bender HG, Kueppers V. Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer. Obstet. Gynecol. 108(6), 1361-1368 (2006). (Pubitemid 44901008)
54. Monk BJ, Burger RA, Lin F, Parham G, Vasilev SA, Wilczynski SP. Prognostic significance of human papillomavirus DNA in vulvar carcinoma. Obstet. Gynecol. 85(5 Pt 1), 709-715 (1995).
55. Hu D, Goldie S. The economic burden of noncervical human papillomavirus disease in the United States. Am. J. Obstet. Gynecol. 198(5), 500-507 (2008).
56. Wiley DJ, Douglas J, Beutner K et al. External genital warts: diagnosis, treatment and prevention. Clin. Infect. Dis. 35(Suppl. 2), S210-S224 (2002). (Pubitemid 35178333)
57. Jansen KU, Shaw AR. Human papillomavirus vaccines and prevention of cervical cancer. Annu. Rev. Med. 55, 319-331 (2004). (Pubitemid 38316730)
58. Garland SM, Steben M, Sings HL et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized Phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J. Infect. Dis. 199(6), 805-814 (2009).
59. Myers ER. The economic impact of HPV vaccines: not just cervical cancer. Am. J. Obstet. Gynecol. 198(5), 487-488 (2008). (Pubitemid 351609024)
60. Fleischer AB, Parrish CA, Glenn R, Feldman SR. Condylomata acuminata (genital warts) - patient demographics and treating physicians. Sex. Transm. Dis. 28(11), 643-647 (2001). (Pubitemid 33055108)
61. Koshiol JE, Laurent SA, Pimenta JM. Rate and predictors of new genital warts claims and genital warts-related healthcare utilization among privately insured patients in the United States. Sex. Transm. Dis. 31(12), 748-752 (2004). (Pubitemid 39557423)
62. Health Protection Agency. Focus on Prevention: HIV and Other Sexually Transmitted Infections in the United Kingdom in 2003 - An Update: November 2004. Health protection Agency, London, UK (2004).
63. Clarke P, Ebel C, Catotti DN, Stewart S. The psychosocial impact of human papillomavirus infection: implications for health care providers. Int. J. STD AIDS 7(3), 197-200 (1996). (Pubitemid 26191688)
64. Maw RD, Reitano M, Roy M. An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle. Int. J. STD AIDS 9, 571-578 (1998). (Pubitemid 28474812)
65. Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin. Infect. Dis. 36, 1397-1403 (2003). (Pubitemid 36702873)
66. Langley PC, White DJ, Drake SM. The costs of treating external genital warts in England and Wales: a treatment pattern analysis. Int. J. STD AIDS 15(8), 501-508 (2004). (Pubitemid 39120231)
67. Lacey CJ, Lowndes CM, Shah KV. Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 24(Suppl. 3), S35-S41 (2006). (Pubitemid 44293033)
68. Giuliano AR, Palefsky JM, Goldstone S et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N. Engl. J. Med. 364(5), 401-411 (2011).
69. Zacharisen MC, Conley SF. Recurrent respiratory papillomatosis in children: masquerader of common respiratory diseases. Pediatrics 118(5), 1925-1931 (2006). (Pubitemid 46393674)
70. Stamataki S, Nikolopoulos TP, Korres S, Felekis D, Tzangaroulakis A, Ferekidis E. Juvenile recurrent respiratory papillomatosis: still a mystery disease with difficult management. Head Neck J. Sci. Special. Head Neck 29(2), 155-162 (2007). (Pubitemid 46167783)
71. Freed GL, Derkay CS. Prevention of recurrent respiratory papillomatosis: role of HPV vaccination. Int. J. Pediatr. Otorhinolaryngol. 70(10), 1799-1803 (2006). (Pubitemid 44291452)
72. Hernandez BY, Barnholtz-Sloan J, German RR et al. Burden of invasive squamous cell carcinoma of the penis in the United States, 1998-2003. Cancer 113(10 Suppl.), 2883-2891 (2008).
73. Rubin MA, Kleter B, Zhou M et al. Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am. J. Pathol. 159(4), 1211-1218 (2001). (Pubitemid 32947950)
74. Miralles-Guri C, Bruni L, Cubilla AL, Castellsague X, Bosch FX, de Sanjose S. Human papillomavirus prevalence and type distribution in penile carcinoma. J. Clin. Pathol. 62(10), 870-878 (2009).
75. Ragin CCR, Modugno F, Gollin SM. The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. J. Dental Res. 86(2), 104-114 (2007).
76. Chung CH, Gillison ML. Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin. Cancer Res. 15(22), 6758-6762 (2009).
77. Mehanna H, Jones TM, Gregoire V, Ang KK. Oropharyngeal carcinoma related to human papillomavirus. BMJ 340, c1439 (2010).
78. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol. Biomark. Prev. 14(2), 467-475 (2005). (Pubitemid 40270113)
79. Syrjanen S, Lodi G, von B, I et al. Human papillomaviruses in oral carcinoma and oral potentially malignant disorders: a systematic review. Oral Dis. 17(Suppl. 1), 58-72 (2011).
80. Stanley M. Prophylactic HPV vaccines: prospects for eliminating ano-genital cancer. Br. J. Cancer 96(9), 1320-1323 (2007). (Pubitemid 46685776)
81. Villa LL, Ault K, Giuliano AR et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16 and 18. Vaccine 24(27-28), 5571-5583 (2006). (Pubitemid 44172918)
82. Giuliano A, Lazcano-Ponce E, Villa L et al. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine. J. Infect. Dis. 196, 1153-1162 (2007). (Pubitemid 47580270)
83. Opalka D, Lachman CE, MacMullen SA et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16 and 18 by a multiplexed luminex assay. Clin. Diagn. Lab. Immunol. 10(1), 108-115 (2003). (Pubitemid 36133838)
84. Brown DR, Garland SM, Ferris DG et al. The humoral response to Gardasil? over four years as defined by Total IgG and competitive Luminex immunoassay. Hum. Vaccin. 7(2), 230-238 (2011).
85. Nakagawa M, Viscidi R, Deshmukh I et al. Time course of humoral and cellmediated immune responses to human papillomavirus type 16 in infected women. Clin. Diagn. Lab. Immunol. 9(4), 877-882 (2002). (Pubitemid 34773894)
86. Olsson S-E, Villa LL, Costa R et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like-particle vaccine. Vaccine 25(26), 4931-4939 (2007). (Pubitemid 46843434)
87. Villa LL, Costa RLR, Petta CA et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br. J. Cancer 95(11), 1459-1466 (2006). (Pubitemid 44863348)
88. Olsson S-E, Kjaer SK, Sigurdsson K et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum. Vaccin. 5(10), 696-704 (2009).
89. Block SL, Nolan T, Sattler C et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 118(5), 2135-2145 (2006). (Pubitemid 46393698)
90. Reisinger KS, Block SL, Collins-Ogle M et al. Safety, tolerability, and immunogenicity of Gardasil given concomitantly with Menactra and Adacel. Pediatrics 125(6), 1142-1151 (2010).
91. Wheeler CM, Bautista OM, Tomassini JE, Nelson M, Sattler CA, Barr E. Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine 26(5), 686-696 (2008).
92. Block SL, Brown DR, Chatterjee A et al. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine. Pediatr. Infect. Dis. J. 29(2), 95-101 (2009).
93. Kroger AT. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb.Mortal. Wkly. Rep. 55(RR-15), 1-48 (2006).
94. Slade BA, Leidel L, Vellozzi C et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 302(7), 750-757 (2009).
95. Markowitz LE, Hariri S, Unger ER, Saraiya M, Datta SD, Dunne EF. Post-licensure monitoring of HPV vaccine in the United States. Vaccine 28(30), 4731-4737 (2010).
96. Bonanni P, Cohet C, Kjaer SK et al. A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD?. Vaccine 28(30), 4719-4730 (2010).
97. Brotherton JML, Deeks S, Campbell-Lloyd S, et al. Interim estimates of human papillomavirus vaccination coverage in the school-based program in Australia. Commun. Dis. Intell. 32, 457-461 (2008).
98. Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex. Transm. Infect. 85(7), 499-502 (2009).
99. Donovan B, Franklin N, Guy R et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet 11(1), 39-44 (2010).
100. Brotherton J, Fridman M, Saville M, Gertig D. First indication of a possible impact on cervical abnormalities following a national HPV vaccination program in Victoria, Australia. Presented at: 26th Annual International Papillomavirus Conference and Clinical Workshop. QC, Canada, 3-8 July 2010.
101. Zimet GD, Rosenthal SL. HPV vaccine and males: issues and challenges. Gynaecol. Oncol. 117(2 Suppl. 1), S26-S31 (2010).
102. Centers for Disease Control and Prevention. National, state, and local area vaccination coverage among adolescents aged 13-17 years - United States, 2009. MMWR Morb.Mortal. Wkly. Rep. 59, 1018-1021 (2010).
103. FUTURE II Study Group. Four year efficacy of prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine against low-grade cervical, vulvar, and vaginal intraepithelial neoplasia and condylomata acuminata. BMJ 340(c3493), 1-9 (2010).
104. Kjaer SK, Sigurdsson K, Iversen O-E et al. A pooled analysis of continued prophylactic efficacy of quadrivalent HPV (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev. Res. 2(10), 868-878 (2009).
105. Munoz N, Kjaer SK, Sigurdsson K et al. Impact of human papillomavirus (HPV)- 6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J. Natl Cancer Inst. 102(5), 325-339 (2010).